Synnat Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 0.07 Cr
as on 17-07-2024
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -30.18%
(FY 2023)
- Profit -39.27%
(FY 2023)
- Ebitda -14.77%
(FY 2023)
- Net Worth 111.79%
(FY 2023)
- Total Assets 10.37%
(FY 2023)
About Synnat Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 0.07 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ramesh Karnani, Siddharth Karnani, and Karnani Ritesh serve as directors at the Company.
- CIN/LLPIN
U24232TG2011PTC074746
- Company No.
074746
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 May 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Secunderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Synnat Pharma Private Limited offer?
Synnat Pharma Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antiviral Drugs, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Common Disease Medicines, Pharmaceutical Tablets.
Who are the key members and board of directors at Synnat Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramesh Karnani  | Director | 31-May-2011 | Current |
| Siddharth Karnani | Director | 03-Dec-2022 | Current |
| Karnani Ritesh | Director | 03-Dec-2022 | Current |
Financial Performance and Corporate Structure Insights of Synnat Pharma.
Synnat Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 30.18% decrease. The company also saw a substantial fall in profitability, with a 39.27% decrease in profit. The company's net worth Soared by an impressive increase of 111.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Synnat Pharma?
In 2023, Synnat Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
14 years 6 months Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Synnat Pharma?
Synnat Pharma has a workforce of 189 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Feb 06, 2012, Synnat Pharma has raised a total of ₹ 0.8 M, with the most recent deal valued at ₹ 0.4 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
